ANITA BELLAIL

president HB Therapeutics, Inc.

Dr. Anita Bellail is the President and Chief Scientific Officer of HB Therapeutics, a biotechnology company pioneering targeted protein degradation strategies to address oncogenic drivers such as KRAS mutants. With over 20 years of experience in the field of protein degradation, Dr. Bellail has led groundbreaking work in the discovery and development of molecular glue degraders and E3 ligase biology. Her leadership at HB Therapeutics is focused on advancing first-in-class therapeutics by harnessing novel degradation mechanisms to tackle previously undruggable targets in cancer.

Seminars

Wednesday 29th October 2025
Uncovering a Dual Molecular Glue Degrader for KRAS Mutants & CRAF: Harnessing Novel E3 Ligase-Mediated Targeted Protein Degradation
12:00 pm

Download the Full Event Guide for Full Session Details.

Anita Bellail